|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,280,000 |
Market
Cap: |
102.22(M) |
Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,824 |
52
Week Range: |
$2.25 - $8.09 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.6 |
Insider 6 Months : 11.3 |
Insider 3/6 Months : 20.1 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
53,764 |
127,764 |
382,819 |
547,434 |
Total Buy Value |
$200,002 |
$419,962 |
$1,081,809 |
$1,686,989 |
Total People Bought |
2 |
4 |
8 |
9 |
Total Buy Transactions |
2 |
4 |
10 |
15 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Salamon Steven A J |
Director |
|
2021-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(877,379) |
404,500 |
|
- |
|
Rosalind Advisors, Inc. |
Director |
|
2021-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(877,379) |
406,500 |
|
- |
|
Aharon Gil |
Director |
|
2021-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(877,379) |
402,000 |
|
- |
|
Salamon Steven A J |
Director |
|
2021-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
877,379 |
404,500 |
|
- |
|
Rosalind Advisors, Inc. |
Director |
|
2021-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
877,379 |
406,500 |
|
- |
|
Aharon Gil |
Director |
|
2021-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
877,379 |
402,000 |
|
- |
|
Purpura John |
Chief Operating Officer |
|
2021-05-13 |
4 |
B |
$9.42 |
$37,680 |
D/D |
4,000 |
18,713 |
2.74 |
-5% |
|
Aharon Gil |
Director |
|
2021-03-31 |
4 |
OE |
$10.00 |
$2,150,000 |
I/I |
215,000 |
402,000 |
|
- |
|
Rosalind Advisors, Inc. |
Director |
|
2021-03-31 |
4 |
OE |
$10.00 |
$2,150,000 |
I/I |
215,000 |
406,500 |
|
- |
|
Salamon Steven A J |
Director |
|
2021-03-31 |
4 |
A |
$10.00 |
$2,150,000 |
I/I |
215,000 |
404,500 |
|
- |
|
Michel Gerard J |
Chief Executive Officer |
|
2020-12-11 |
4 |
B |
$13.25 |
$99,375 |
D/D |
7,500 |
7,500 |
2.81 |
-28% |
|
Purpura John |
Chief Operating Officer |
|
2020-11-19 |
4/A |
B |
$12.68 |
$20,288 |
D/D |
1,600 |
14,721 |
2.74 |
- |
|
Purpura John |
Chief Operating Officer |
|
2020-11-19 |
4 |
B |
$12.68 |
$20,288 |
D/D |
1,600 |
14,713 |
2.74 |
-5% |
|
Rosalind Advisors, Inc. |
Director |
|
2020-11-17 |
4 |
B |
$12.11 |
$30,280 |
I/I |
2,500 |
191,500 |
2.1 |
32% |
|
Salamon Steven A J |
Director |
|
2020-11-17 |
4 |
B |
$12.11 |
$30,280 |
D/D |
2,500 |
189,500 |
2.39 |
32% |
|
Aharon Gil |
Director |
|
2020-11-16 |
4 |
B |
$12.00 |
$24,000 |
D/D |
2,000 |
187,000 |
2.39 |
35% |
|
Rosalind Advisors, Inc. |
Director |
|
2020-11-13 |
4 |
B |
$11.75 |
$47,000 |
I/I |
4,000 |
189,000 |
2.1 |
44% |
|
Salamon Steven A J |
Director |
|
2020-11-13 |
4 |
B |
$11.51 |
$23,020 |
I/I |
2,000 |
187,000 |
2.1 |
44% |
|
Taglietti Marco |
Director |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
|
- |
|
Purpura John |
See Remarks |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
13,121 |
|
- |
|
Simpson Jennifer K. |
President and CEO |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
14,700 |
25,021 |
|
- |
|
Stoll Roger G Phd |
Director |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,300 |
9,309 |
|
- |
|
Keck Barbra |
See Remarks |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
12,851 |
|
- |
|
Rueckert William Dodge |
Director |
|
2020-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,014 |
|
- |
|
Purpura John |
See Remarks |
|
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,613 |
6,621 |
|
- |
|
118 Records found
|
|
Page 3 of 5 |
|
|